Clinical trial · Interventional
Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors
Phase I Study To Determine The Safety Of Halofuginone In Patients With A Solid Progressive Tumor
NCT00027677CI-TRIAL-00007537completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Halofuginone hydrobromide may stop the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of halofuginone hydrobromide in treating patients who have progressive advanced solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| halofuginone hydrobromide | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed advanced solid tumor that is not amenable to any clinical improvement by current standard treatments * No tumors of the upper digestive tract * No clinical signs of CNS involvement PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-2 OR * WHO 0-2 Life expectancy: * At least 12 weeks Hematopoietic: * WBC at least 3,000/mm\^3 * Neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Hemoglobin at least 10.0 g/dL Hepatic: * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * AST and ALT no greater than 2.5 times ULN * No unstable hepatobiliary disease that would preclude study Renal: * Creatinine no greater than 1.5 times ULN * No unstable renal disease that would preclude study Cardiovascular: * No unstable cardiovascular disease (e.g., stroke) that would preclude study Pulmonary: * No unstable pulmonary disease that would preclude study Gastrointestinal: * No digestive disease, including upper gastrointestinal tract, that would hamper absorption * No evident/known lactose malabsorption Other: * No allergy to components of the study drug * No uncontrolled infection * No other unstable systemic disease that would preclude study * No psychological, familial, sociological, or geographical condition that would preclude compliance * Not pregnant * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after study PRIOR CONCURRENT THERAPY: Biologic therapy: * At least 4 weeks since prior anticancer biologic therapy Chemotherapy: * At least 4 weeks since prior anticancer chemotherapy Endocrine therapy: * Prior anticancer hormonal therapy allowed Radiotherapy: * At least 6 weeks since prior radiotherapy * No concurrent radiotherapy Surgery: * At least 2 weeks since prior surgery Other: * At least 4 weeks since other prior anticancer treatment * No other concurrent anticancer agents or investigational therapy
References
Publications (0)
Data not yet available
No reference posted for this study.